Advancing a High-Value
Therapeutic Pipeline.
Structured preclinical validation driving toward rapid Phase I/II clinical readouts and strategic biopharmaceutical partnership milestones.
Development Programs & Clinical Stages
Four targeted indications addressing acute, chronic, and emergency wound-healing deficits using tailored delivery modalities.
Diabetic Foot Ulcers (DFU)
Delivery Modality: Topical Gel
Targeted candidate for stalled chronic neuropathic and neuroischemic diabetic foot ulcers. Demonstrates 2X acceleration in closure rate at Day 10.
Venous Leg Ulcers (VLU)
Delivery Modality: Matrix Sheet
Designed to work synergistically under multi-layer compression wraps for chronic venous insufficiency wounds.
Deep Partial-Thickness Burns & Trauma
Delivery Modality: Topical Spray
Rapid field deployment candidate for thermal burn debridement and trauma wound triage without requiring cold chain logistics.
Surgical Incision Dehiscence & High-Tension Closures
Delivery Modality: Extended-Release Candidate
Designed to enhance tissue tensile strength and prevent surgical breakdown in high-risk incisions.
Capital Efficiency & Targeted Use of Funds
Structured to maximize clinical value inflection points through Phase Ib human readouts.
Phase Ib Clinical Trial
Execution of 60-patient DFU open-label safety and preliminary re-epithelialization trial.
GLP Tox & CMC Scale-Up
Porcine GLP safety validation and commercial-grade cGMP batch manufacturing.
Pipeline Indication Expansion
Preclinical validation across expanded chronic ulcer and thermal burn indications.
Regulatory & G&A
Legal, regulatory filings, and general operating costs through Phase Ib.
Partner With ZegeneX
Explore co-development collaborations, territory licensing rights, and institutional investment opportunities in our lead and pipeline assets.
Request Partnering Package & Data Room Access